An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 21, Issue 4, 2005, Pages 347-352

  Schiaffini, Riccardo ^a   Ciampalini, Paolo ^a   Spera, Sabrina ^a   Cappa, Marco ^a   Crinó, Antonino ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Basal insulin supplementation; CSII; Insulin Glargine; Type 1 diabetes

Indexed keywords

FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

ADOLESCENT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME;

BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; RETROSPECTIVE STUDIES;

EID: 21744456422     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.520     Document Type: Article

References (34)

1. Pickup JC, Keen H, Parsons J, Alberti K. Continuous subcutaneous insulin infusion: an approach to achieve normoglycaemia. Br J Med 1978; 1: 204-207.
2. Pickup JC, Keen H. Continuous subcutaneous insulin infusion at 25 years. Diabetes Care 2002; 25(3): 593-598.
3. Pickup JC, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002; 324: 1-6.
4. Ahern JAH, Boland EA, Doane R, et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatric Diabetes 2002; 3: 10-15.
5. Schiaffini R, Ciampalini P, Fierabracci A, et al. The continuous glucose monitoring system (CGMS) in type 1 diabetic children is the way to reduce the hypoglycemic risk. Diabetes Metab Res Rev 2002; 18(4): 324-329.
6. Tamborlane WV, Bonfig W, Boland E. Recent advances in treatment of youth with type 1 diabetes: better care through technology. Diabet Med 2001; 18: 864-870.
7. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
8. Kuerzel GU, Shukla U, Scholtz HE, et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003; 19(1): 34-40.
9. Madsbad S. Insulin analogues: have they changed insulin treatment and improved glycaemic control?. Diabetes Metab Res Rev 2002; 18(Suppl 1): S21-S28.
10. Bolli GB. Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001; 109(Suppl 2): S317-S332.
11. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 3: 188-199.
12. Brange J, Langkjaer L. Insulin formulation and delivery. Pharm Biotechnol 1997; 10: 343-409.
13. Rosenstock J, Park G, Zimmerman J. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000; 23(8): 1137-1142.
14. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. U.S. Insulin Glargine (HOE 901.) Type 1 Diabetes Investigator Group. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23(5): 639-643.
15. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimes using insulin lispro in type 1 diabetic patients on intensified treatment. Diabetes Care 2000; 23(9): 1232-1235.
16. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes. Diabetes Care 2000; 26(9): 2598-2603.
17. Schiffrin AD, Desrosiers M, Hassan Aleyassine RN, Belmonte MM. Intensified insulin therapy in the type 1 diabetic adolescent: a controlled trial. Diabetes Care 1984; 7: 107-113.
18. Kanc K, Jannssen MMJ, Keulen ETP, et al. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM. Diabetologia 1998; 41: 322-329.
19. Hamann A, Matthaei S, Rosak C, Silvestre L. HOE901/4007 Study Group. A randomized clinical trial comparing breakfast, dinner or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003; 26: 1738-1744.
20. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Pediatric study group of insulin glargine: comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002; 15(4): 369-376.
21. Murphy NP, Keane SM, Ong KK, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003; 26(3): 799-804.
22. King AB, Armstrong D. A comparison of basal insulin delivery. Diabetes Care 2003; 26(4): 1322.
23. Lepore G, Dodesini AR, Nosari I, Trevisan R. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Diabetes Care 2003; 26(4): 1321-1322.
24. Home PD, Ashwell SG. An overview of insulin glargine. Diabetes Metab Res Rev 2002; 18(Suppl 3): S57-S63.
25. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
26. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26(11): 3160-3167.
27. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
28. Nordfeldt S, Ludvigsson J. Adverse events in intensively treated children and adolescents with type 1 diabetes. Acta Paediatr 1999; 88(11): 1184-1193.
29. Ludvigsson J, Bolli GB. Intensive insulin treatment in diabetic children. Diabetes Nutr Metab 2001; 14(5): 292-304.
30. Schade DS, Valentine V. To pump or not to pump. Diabetes Care 2002; 25(11): 2100-2102.
31. Hathout EH, Fujishige L, Geach J, Ischandar M, Maruo S, Mace JW. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol Ther 2003; 5(5): 801-806.
32. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004; 27(7): 1554-1558.
33. Armstrong DU, King AB. Basal insulin: continuous glucose monitoring reveals less overnight hypoglycemia with continuous subcutaneous insulin infusion than with glargine (Abstract). Diabetes 2002; 51(Suppl. 2): A92.
34. Alemzadeh R, Ellis JN, Holzum MK, Parton EA, Wyatt DT. Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes. Pediatrics 2004; 114(1): E91-95.